FDA cracks down on illegal supplements

Dec 15, 2010

(AP) -- The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients.

The FDA said Wednesday that some manufacturers are deceptively labeling products to hide that they contain ingredients known to cause . Other supplements contain ingredients that should only be available by prescription.

"These tainted products can cause serious , including strokes, , and death," said FDA Commissioner Margaret Hamburg. "The manufacturers selling these tainted products are operating outside the law."

can slip through the regulatory cracks because, unlike drugs, they do not have to be approved by the FDA before they are marketed. Manufacturers are responsible for making sure their products are safe.

The FDA has pressured companies to recall nearly 200 inappropriately-formulated products since 2007, including 80 that were marketed as body building supplements, according to the agency. The recalled products were linked to reports of stroke, , and death.

Government regulators do not have the power to force companies to recall products, and instead the FDA usually issues warning letters to draw attention to illegal products.

In a letter to the supplement industry, the agency said manufacturers who distribute tainted products could face criminal prosecution.

Executives from the supplement industry said they support the FDA crackdown and would share the letter with companies.

"The spiking of supplements with drugs is a crime, it endangers the public and undermines our members and other legitimate manufacturers and retailers of supplements," said John Gay, executive director of the Natural Products Association, on a media call with FDA leadership.

The FDA said the agency is targeting weight loss products containing sibutramine, which has been withdrawn from the market for causing increased risk of heart attack and stroke. The agency said it has discovered "dozens of products" that contain the ingredient, including those marketed under the brand names Slimming Beauty, Solo Slim and Slim-30.

Body building products under scrutiny include those containing anabolic steroids or steroid analogs. The agency cited Tren Xtreme, ArimaDex, and Clomed as supplements that have been labeled to contain those products.

The agency also warned consumers to be wary of sexual enhancement products that include similar ingredients to the approved drugs Viagra, Cialis, and Levitra. Those ingredients should only be available by prescription. The FDA said products marketed under the names Vigor-25, Duro Extend Capsules for Men, and Magic Power Coffee have been determined to be in violation of federal law.

"Consumers should avoid products marketed as supplements that claim to have effects similar to prescription drugs," said Michael Levy, director of labeling compliance for the agency. "Consumers should also be wary of products with labeling only in a foreign language or that are marketed through mass e-mails."

Explore further: FDA approves new drug for rare genetic disease

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA seizes sexual enhancement products

Apr 10, 2008

The U.S. Food and Drug Administration announced the seizure by U.S. marshals of more than 14,000 units of Shangai- and Naturale-brand diet supplements.

FDA issues supplement rules

Jun 23, 2007

The U.S. Food and Drug Administration has issued new government standards for the manufacture of vitamins and dietary supplements.

Nanotech in your vitamins

Jan 14, 2009

The ability of the Food and Drug Administration (FDA) to regulate the safety of dietary supplements using nanomaterials is severely limited by lack of information, lack of resources and the agency's lack of statutory authority ...

FDA cracks down on hydrocone products

Sep 29, 2007

The U.S. Food and Drug Administration says it will start taking enforcement action against companies marketing unapproved hydrocodone products.

Recommended for you

Boxed warnings are common in novel therapeutics

16 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

18 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

19 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0